Fragile X Syndrome

The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started recruiting participants for the first-ever clinical trial assessing the effects of psilocybin in adults diagnosed with Fragile X Syndrome (FXS), the leading genetic...

Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a genetic disorder. KGK and its client Nova Mentis (OTC: NMLSF) are set to conduct this pioneering...

The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a No Objection letter and is set to proceed with the first-ever Phase 2a clinical trial on the magic...

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares were trading higher Tuesday after the cannabinoid devloper posted its financial report for the fourth quarter and full year 2019. The company reported zero revenue versus $86,000 in the fourth quarter of 2018.  For the quarter, the...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a company that focuses on treating rare and near-rare neuropsychiatric disorders through cannabinoid therapies, said Tuesday it received a new U.S. patent for one of its cannabis-focused treatments. Zynerba said the U.S. Patent and Trademark Office...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) investors may have reason for cautious optimism after the company’s recent Fragile X Syndrome treatment data. On Monday, Cantor Fitzgerald analyst Elemer Piros upgraded Zynerba to Overweight and said there is a reasonable change ZYN002 will find...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) traded up as much as 82.6 percent Thursday after reporting positive top-line results for its uncontrolled phase 2 study of ZYN002 in children with Fragile X syndrome. The synthetic cannabinoid transdermal gel “successfully met its primary endpoint...

The Cowen Group has initiated coverage on Ovid Therapeutics Inc (NASDAQ: OVID) with an Outperform rating and $14.48 price target. It's Time To Tackle Orphan Neurological Disorders Until now, the biopharmaceutical industry has mostly ignored orphan neurological disorders due to the difficulty of...

Despite confirming third-quarter catalysts and progress throughout its development pipeline, Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)’s first-quarter financial report didn’t impress investors. The company conceded an 8.3-percent stock decline Tuesday even as it boasts a 22-percent...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is about to embark upon a journey with unknown destinations, as investors brace for a trio of reads from the company in the third quarter of 2017. Focus: 3 Phase 2 Reads Of ZYN002 Cantor Fitzgerald said in a note released Monday it remains focused on...

Alzheimer's has proven to be one of the most stubborn diseases known to modern medicine. An incurable, devastating illness that inspires frustration — even anger — against and from the scientific community itself, which has failed to develop new, effective therapies. Susanne...

Cantor Fitzgerald said in a note on Tuesday Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is poised to have three data readouts in the first half of 2017. Analyst Elemer Piros noted that the company reported the initiation of its FAB-C Phase II study with ZYN002 in children with Fragile X...

H.C. Wainwright & Co. believes that the current valuation of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) has not taken into consideration the potential increased success rate of ZYN002 for epilepsy. Therefore, the firm believes the stock has the potential to deliver more than 60 percent upside...